Loading clinical trials...
Loading clinical trials...
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. A Multicenter, Open-label, Phase II Trial
Conditions
Interventions
Ibrutinib
Venetoclax
Locations
11
Switzerland
Kantonsspital Aarau
Aarau, Switzerland
Universitätsspital Basel
Basel, Switzerland
IOSI - Ospedale San Giovanni
Bellinzona, Switzerland
Inselspital
Bern, Switzerland
Kantonsspital Graubünden
Chur, Switzerland
Kantonsspital Liestal
Liestal, Switzerland
Start Date
March 11, 2019
Primary Completion Date
November 30, 2025
Completion Date
November 30, 2025
Last Updated
December 30, 2025
NCT06735690
NCT00131014
NCT05564390
NCT06074666
NCT03050268
NCT06846671
Lead Sponsor
Swiss Cancer Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions